Pliant Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Pliant Therapeutics, Inc. filed a Form 8-K on February 28, 2022, under Item 2.02 to announce financial results for the fourth quarter and year ended December 31, 2021. The filing furnishes the related press release as Exhibit 99.1.
Financial results and key metrics
The provided filing text does not include the press release content or clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Material changes versus the prior comparable period
The filing text does not provide comparative financial data or describe material changes versus the prior-year quarter or year.
Guidance, outlook, risks, and unusual items
The filing text does not provide management guidance, outlook, risk updates, contingencies, or unusual items. The Form 8-K states that the information furnished under Item 2.02 and the related exhibit is not deemed filed for purposes of Section 18 of the Exchange Act.
Important facts to verify
- Review Exhibit 99.1 for the complete fourth-quarter and full-year 2021 financial results.
- Verify reported cash, cash equivalents, investments, operating cash usage, and expected liquidity runway.
- Verify revenue, operating expenses, net loss, loss per share, and any non-GAAP measures.
- Review management’s pipeline updates, clinical-development plans, guidance, and disclosed risks.